Michael J. Farrell - Jun 7, 2024 Form 4 Insider Report for RESMED INC (RMD)

Signature
Michael J. Farrell, Chief Executive Officer
Stock symbol
RMD
Transactions as of
Jun 7, 2024
Transactions value $
-$1,859,978
Form type
4
Date filed
6/10/2024, 09:58 PM
Previous filing
May 14, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $1.25M +14.7K +3.33% $84.98 455K Jun 7, 2024 Direct F1
transaction RMD ResMed Common Stock Sale -$3.11M -14.7K -3.22% $211.66 441K Jun 7, 2024 Direct F1, F2, F3
holding RMD ResMed Common Stock 0 Jun 7, 2024 Lisette and Michael Farrell Foundation
holding RMD ResMed Common Stock 4.09K Jun 7, 2024 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -14.7K -16.67% $0.00 73.4K Jun 7, 2024 ResMed Common Stock 14.7K $84.98 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $210.58 - $213.86. The price reported above reflects the weighted average sale price.
F3 Includes 46.9596 shares of ResMed stock purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan.
F4 Represents date options first became exercisable. Options vest 1/3 per year.